Seizure News and Research

Latest Seizure News and Research

Forest Labs enters definitive merger agreement to acquire Clinical Data

Forest Laboratories, Inc. and Clinical Data, Inc. today announced that they have entered into a definitive merger agreement pursuant to which Forest will acquire Clinical Data, a specialty pharmaceutical company focused on the development of first-in-class and best-in-category therapeutics, for $30.00 per share in cash plus contingent consideration of up to $6.00 per share that may be paid upon achievement of certain commercial milestones related to Viibryd.

22 Feb 2011

Healthcare disparities seen in epilepsy patients with low socioeconomic status

A newly published report reveals patients with epilepsy and low socioeconomic status (SES) are more likely to have uncontrolled seizures, drug-related side effects, and a lower overall quality of life. The study also indicates that low SES patients used the hospital emergency room more often and had more visits to a general practitioner than epileptic patients at higher socioeconomic levels. Full findings are now available in Epilepsia, a journal published by Wiley-Blackwell on behalf of the International League Against Epilepsy.

22 Feb 2011

Epilepsy patients with low SES more likely to have poor quality of life

A newly published report reveals patients with epilepsy and low socioeconomic status are more likely to have uncontrolled seizures, drug-related side effects, and a lower overall quality of life.

22 Feb 2011

New research: Fluid retention may explain drugs' risk of strokes and heart attacks

New research shows that medications which have raised safety concerns over heart attack and stroke risks may not have gotten approval from the Food and Drug Administration if the cardiovascular effects of fluid retention had been better understood. Fluid retention may explain the increased risk of heart attacks and strokes of medications such as Vioxx, Bextra, and Avandia.

22 Feb 2011

Frequent, potentially avoidable readmissions are major driver of pediatric health care costs

Among a group of children's hospitals, nearly 20 percent of admissions and one-quarter of inpatient expenditures were accounted for by a small percentage of patients who have frequent recurrent admissions, according to a study in the February 16 issue of JAMA.

18 Feb 2011

Longer looks: KHN's best health policy picks from thought-provoking publications

A law under consideration in South Dakota would expand the definition of "justifiable homicide" to include killings that are intended to prevent harm to a fetus—a move that could make it legal to kill doctors who perform abortions.

18 Feb 2011

Acorda reports fourth quarter net revenue of $133.1 million for full year ended December 31, 2010

Acorda Therapeutics, Inc. today announced its financial results for the fourth quarter and full year ended December 31, 2010.

17 Feb 2011

Harmful effects of energy drinks on children

A new study published in the journal Pediatrics on Monday examined the risks of consumption of high-caffeine energy drinks on children and young adults. The study notes that these drinks are linked to an array of serious events like heart palpitations, high blood pressure and even cardiac arrest and death. The risk rises if young adults consuming the drink suffer from chronic diseases or take other medications.

14 Feb 2011

Questcor's pricing issue

After Questcor Pharmaceuticals raised the price of the drug Acthar, its sole product, more than 10-fold in 2007, its shares began a climb from pennies to $14 and change. Acthar

14 Feb 2011

First Edition: February 14, 2011

Today's headlines are focused on President Obama's budget proposal and what it does and does not include.

14 Feb 2011

Genentech's OCEANS Phase III study of Avastin in platinum-sensitive ovarian cancer meets primary endpoint

Genentech, a member of the Roche Group, announced today that OCEANS, a Phase III study evaluating Avastin® (bevacizumab) in combination with chemotherapy (carboplatin and gemcitabine) followed by continued use of Avastin alone until disease progression in women with previously treated (recurrent), platinum-sensitive ovarian cancer, met its primary endpoint.

8 Feb 2011

Vascular birthmarks can cause concern for parents: Dermatologists

Vascular birthmarks, which occur in nearly 10 percent of all infants at birth or within the first few weeks of life, can cause concern for parents particularly if they are large or in a cosmetically important area. The decision to treat a birthmark is one that parents should make with a dermatologist, who can determine the type of birthmark and whether or not it poses any potential risks in the future.

5 Feb 2011

North Shore-LIJ begins patient enrollment in epilepsy research study

In the United States, epilepsy affects nearly one million women of childbearing potential and whether there is increased infertility in women with epilepsy is presently unknown. People with epilepsy have been reported to have fewer children, however, the specific factors contributing to this lower birth rate are unknown.

5 Feb 2011

Pediatric neurosurgery patient named Grand Marshal of 2011 Go the Distance fundraising event

A quiet, peaceful evening last summer quickly turned into a nightmare for parents Amanda and Bryan Tormey when they were awoken by sounds of their three year-old son, Nathan, stirring in his bed. When they checked on him, the cause of Nathan's restlessness became frighteningly evident; Nathan was in the midst of massive seizure that would ultimately incapacitate him for several hours.

4 Feb 2011

Concert and WRAIR enter CRADA to evaluate novel compound for seizure protection associated with TBI

Concert Pharmaceuticals, Inc. today announced that it has entered into a Cooperative Research and Development Agreement with the Walter Reed Army Institute of Research. The CRADA will allow the WRAIR to conduct preclinical testing on a novel compound derived from Concert's DCE Platform™ (deuterated chemical entity platform) for seizure protection associated with traumatic brain injury, a major public health concern.

3 Feb 2011

Merck announces publication of GARDASIL pivotal Phase III study data in NEJM

Merck announced today that data from the pivotal Phase III study with GARDASIL in males were published in the February 3 issue of the New England Journal of Medicine.

3 Feb 2011

FDA approves Cyberonics Aspire High Capacity generator for vagus nerve stimulation therapy

Cyberonics, Inc. today announced that the AspireHC™ (High Capacity) generator for use in vagus nerve stimulation (VNS) therapy was approved by the United States Food and Drug Administration (FDA) for commercial release.

2 Feb 2011

Phase III study shows tapentadol ER relieves chronic pain associated with DPN

New research has been published indicating that patients suffering from a painful complication of diabetes may experience a significant improvement in their pain as measured by a pain intensity scale when using an investigational pain medication.

29 Jan 2011

Eisai to seek marketing authorization for perampanel in the U.S. and EU

Eisai announced today that it will submit Marketing Authorization Applications in the United States and the European Union for the investigational compound perampanel (E2007) based on the results of three Phase III pivotal studies. Perampanel is a first-in-class, highly selective non-competitive AMPA-type glutamate receptor antagonist, discovered and being developed by Eisai for adjunctive treatment of partial onset seizures in patients with epilepsy.

25 Jan 2011

Composer Fr-d-ric Chopin probably had temporal lobe epilepsy

The composer Fr-d-ric Chopin, who regularly hallucinated, probably had temporal lobe epilepsy throughout his short life, reveals research published online in Medical Humanities. Hallucinations typically feature in seizure disorders, they say.

25 Jan 2011

Seizure News and Research

Latest Seizure News and Research

Forest Labs enters definitive merger agreement to acquire Clinical Data

Healthcare disparities seen in epilepsy patients with low socioeconomic status

Epilepsy patients with low SES more likely to have poor quality of life

New research: Fluid retention may explain drugs' risk of strokes and heart attacks

Frequent, potentially avoidable readmissions are major driver of pediatric health care costs

Longer looks: KHN's best health policy picks from thought-provoking publications

Acorda reports fourth quarter net revenue of $133.1 million for full year ended December 31, 2010

Harmful effects of energy drinks on children

Questcor's pricing issue

First Edition: February 14, 2011

Genentech's OCEANS Phase III study of Avastin in platinum-sensitive ovarian cancer meets primary endpoint

Vascular birthmarks can cause concern for parents: Dermatologists

North Shore-LIJ begins patient enrollment in epilepsy research study

Pediatric neurosurgery patient named Grand Marshal of 2011 Go the Distance fundraising event

Concert and WRAIR enter CRADA to evaluate novel compound for seizure protection associated with TBI

Merck announces publication of GARDASIL pivotal Phase III study data in NEJM

FDA approves Cyberonics Aspire High Capacity generator for vagus nerve stimulation therapy

Phase III study shows tapentadol ER relieves chronic pain associated with DPN

Eisai to seek marketing authorization for perampanel in the U.S. and EU

Composer Fr-d-ric Chopin probably had temporal lobe epilepsy

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Seizure News and Research

Latest Seizure News and Research

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Newsletters you may be interested in